首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2099353

體外診斷（IVD）：市場洞察、競爭格局和市場預測 - 2034 年

In Vitro Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034

出版日期: 2026年07月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

體外診斷（IVD）市場概述

概述：

體外診斷（IVD）市場到2025年達到 1,128億美元，預計到2034年將達到 1,894億美元。該成長是由全球慢性疾病和感染疾病負擔加重、分子診斷和檢查室自動化技術的快速發展以及即時檢測和個人化檢測的日益普及所推動的。
全球體外診斷市場預計在2026年至2034年的預測期內將以 6.0%的CAGR成長。
依產品類型分類，到2025年，試劑區隔佔 65%的市場佔有率，推動體外診斷市場的發展。
按檢測方法分類，到2025年，免疫診斷領域佔體外診斷市場 29%的佔有率，並引領體外診斷市場。
就測試類型而言，「檢查室測試」細分市場到2025年引領體外診斷市場，佔 82%的佔有率。
就檢體類型而言，到2025年，血液樣本引領體外診斷市場，佔據 54%的市場佔有率。
依應用領域分類，到2025年，感染疾病領域引領體外診斷市場，佔據 40%的市場。
依最終用戶，到2025年，醫院領域引領體外診斷市場，佔據 44%的市場。
到2025年，北美佔據 39%的市場佔有率，推動全球體外診斷銷售，並成為全球市場佔有率最高的地區。

體外診斷（IVD）指的是用於檢測、診斷、監測和管理疾病及健康狀況的測試、試劑、儀器和系統，其原理是透過檢測血液、尿液和唾液等體外檢體。 IVD 產品種類繁多，從簡單的側向流動試紙到全自動高通量實驗室分析儀，再到複雜的分子診斷和次世代定序平台，為醫院、診斷檢查室、診所和家庭環境中的大量臨床決策提供支援。該市場依產品類型（儀器、試劑和其他耗材）、技術（免疫診斷、血液學、分子診斷、臨床化學等）、測試類型（檢查室檢測和即時檢測（POC））以及檢體類型（主要為血液、尿液和唾液）細分。應用領域包括腫瘤學、免疫學、感染疾病、循環系統和腎臟病學。最終用戶主要是醫院和診斷檢查室。受慢性疾病和感染疾病在全球範圍內日益加重、人口老化、個人化醫療和伴隨診斷的轉變以及分子檢測、自動化和數位檢測工作流程的不斷創新所推動，體外診斷已成為支持現代循證醫療保健服務的重要基礎設施。

體外診斷市場的主要成長促進因素

全球慢性疾病和感染疾病負擔日益加重，推動了診斷檢測的成長，其中心血管疾病、糖尿病、癌症和呼吸道感染疾病導致對檢查室檢測和即時檢測的需求持續成長。
包括次世代定序、自動化免疫檢測平台和人工智慧整合檢測流程在內的快速技術進步，提升診斷的速度、準確性和處理能力。Roche公司於2025年2月推出的SBX定序平台就是一個典型的例子。
即時檢測技術的日益普及，使診斷工作不再集中於中心檢查室，能夠讓醫院、診所和社區醫療機構更快地做出臨床決策。
隨著個人化醫療和伴隨診斷的擴展，對基於生物標記的腫瘤檢測的需求日益成長，以便為每位患者確定最合適的標靶治療。
隨著世界人口老化，對慢性病監測和預防性篩檢的需求不斷成長，預計2015年至2050年間，60 歲及以上人口將增加近一倍。
隨著一系列監管部門的批准，包括2025年 11月 FDA 批准和 CE-IVDR 認證，BD 的BD COR 系統中的腸道細菌檢測板獲得了批准，可進行的檢測範圍日益擴大。
由於併購和投資活動的活性化，競爭格局重組，技術組合也在擴大，例如 QIAGEN 計劃收購 Parse Biosciences 以及 Abbott 計劃在2026年收購 Exact Sciences。

推動體外診斷市場成長的因素

市場促進因素

全球慢性病和感染疾病負擔日益加重

體外診斷市場最強勁的驅動力是全球慢性病和感染疾病負擔的日益惡化。心血管疾病、糖尿病、癌症和呼吸系統疾病的盛行率持續上升，而愛滋病、結核病、肝炎和季節性呼吸道病原體等感染疾病仍然是重大的公共衛生挑戰。所有這些疾病的診斷、分期和持續監測都依賴檢查室檢測和即時檢測，這使得醫院、診斷檢查室和社區醫療機構對檢測的需求持續旺盛。隨著疾病盛行率的上升和篩檢計畫的擴展，對免疫診斷、分子診斷、血液學和臨床化學檢測的需求也在不斷成長，這為2034年之前體外診斷設備、試劑和服務的強勁長期需求奠定了基礎。

分子診斷和自動化領域的技術進步

分子診斷、次世代定序和檢查室自動化領域的持續創新拓展體外診斷（IVD）的臨床效用和普及程度。自動化高通量分析儀縮短了結果報告時間並最大限度地減少了人為錯誤，而多分子檢測平台則能夠從單一檢體同時檢測多種病原體和生物標記。Roche於2025年2月發表的SBX（擴展定序）平台清楚展現了平台創新的快速發展，並且改變分子診斷的模式。人工智慧整合的實驗室資訊系統和數位病理工具進一步提高了診斷準確性和工作流程效率。在人員短缺的情況下，檢查室對其基礎設施進行現代化改造，以應對不斷成長的檢測量，而新一代自動化和分子診斷平台的應用也在持續加速，推動市場的持續成長。

市場限制因素

儘管潛在需求強勁，體外診斷市場仍面臨諸多限制因素。各大醫療體系的定價和償付壓力擠壓利潤空間，尤其是在大批量試劑和耗材領域；同時，保險公司也日益關注新型分子診斷和伴隨診斷測試的成本效益。包括歐盟體外醫療設備法規（IVDR）在內的嚴格且不斷變化的法規結構，顯著延長了核准時間並增加了合規成本，給中小製造商和利基測試開發商帶來了不成比例的負擔。自動化分析儀和分子診斷平台所需的高額前期投資限制了小規模檢查室和新興市場的應用。此外，參考檢查室網路的整合集中採購力量，加劇供應商之間的價格競爭。一些地區熟練的檢查室和分子診斷專家短缺，限制了產能擴張；而圍繞互聯診斷平台和檢查室資訊系統的資料隱私、互通性和網路安全問題，則進一步加劇了市場的複雜性。儘管疾病負擔、技術創新和個人化醫療等潛在促進因素依然強勁，但由於地區償付制度的差異、先進檢測方法的普及以及試劑租賃合約等大宗交易類別持續的價格壓力等多種因素，成長速度放緩。

區域性說明

北美洲

到2025年，北美佔全球體外診斷（IVD）市場收入的39%。美國憑藉其在醫療保健基礎設施、密集的檢查室網路、清晰的FDA法規和健全的保險償付環境方面的優勢，在該市場佔據主導地位。主要製造商對自動化血液檢測、免疫檢測和分子診斷平台的持續投資，進一步鞏固了其領先地位。

歐洲

歐洲是一個龐大且發達的區域市場，擁有完善的EMA和IVDR法規結構、健全的公共醫療體係以及Roche、Siemens Healthcare、bioMerieux等強大的診斷設備製造商基礎。bioMerieux計劃在法國投資超過2.5億歐元新建一座生產其BIOFIRE分子檢測產品線的工廠，這將進一步鞏固歐洲在向德國、法國、英國、義大利和西班牙供應診斷試劑和設備方面的地位。

亞太地區

亞太地區是成長最快的地區，這主要得益於中國、日本、印度、韓國和澳洲疾病發病率的上升、醫療基礎設施的快速發展以及醫療投資的不斷成長。 Sysmex持續部署新一代血液檢測平台，以及Siegen多重分子診斷產品組合的擴展，加速該地區相關技術的應用和產能成長。

世界其他地區

世界其他地區，包括拉丁美洲、中東和非洲，正成為新興的成長前線。隨著醫療基礎設施的完善、感染疾病和慢性病檢測需求的成長，以及法規結構與國際標準的接軌，該地區的醫療服務可近性逐漸擴大。國際夥伴關係和政府間協議，例如奈及利亞與Abbott和Siemens健康保險公司簽署的《2024年診斷基礎設施協議》，也為該地區檢測能力的提升提供了支持。

體外診斷市場近期發展趨勢

2025年2月，Roche公司推出SBX（擴展定序）平台，進一步拓展了其分子診斷與定序技術產品組合。策略意義：此舉增強了Roche的次世代定序能力，並鞏固了其作為綜合診斷服務提供者的主導地位。

2026年，Abbott完成了對Exact Sciences的收購，顯著擴展了其癌症篩檢和診斷產品組合。戰略意義：此次收購增強了Abbott在癌症診斷和伴隨診斷（關鍵成長領域）的市場佔有率。

常見問題：

問題1：體外診斷市場的成長率是多少？

預計從2026年到2034年的預測期內，體外診斷市場將以 6.0%的CAGR成長。

Q2.體外診斷市場的市場規模有多大？

2025年體外診斷市場規模估計為1,128億美元，預計2034年將達到1,894億美元。

Q3.哪一個地區是體外診斷市場的主要驅動力？

憑藉著高度發展的醫療保健基礎設施、廣泛的檢測實驗室網路、健全的保險償付體系、清晰的FDA法規以及主要製造商的存在，北美主導體外診斷市場，到2025年佔全球銷售額的39%。亞太地區預計將成為預測期內成長最快的地區。

第四季：體外診斷市場的主要促進因素是什麼？

關鍵促進因素包括慢性病和感染疾病在全球範圍內日益加重的負擔、分子診斷、自動化和人工智慧整合檢測工作流程的快速技術進步、即時檢測的日益普及、個性化醫療和伴隨診斷的擴展、全球人口老齡化以及診斷行業併購和投資活動的活性化。

Q5.體外診斷市場的主要參與者有哪些公司？

主要參與者包括F. Hoffmann-La Roche Ltd、Abbott、FUJIFILM Corporation、Sysmex Corporation、Siemens Healthcare GmbH、BD、Seegene Inc、Beckman Coulter, Inc (Danaher Corporation)、QIAGEN、bioMerieux SA以及「競爭格局」部分中描述的其他活躍企業。F. Hoffmann-La Roche Ltd、Abbott、Siemens Healthcare GmbH、Beckman Coulter憑藉其廣泛多元的產品系列和全球分銷網路，在市場中佔據領先地位。

體外診斷市場：市場促進因素
- 慢性疾病和感染疾病負擔日益加重
- 分子診斷技術的進步
- 擴大即時偵測的應用範圍。
- 個性化醫療和伴隨診斷的擴展
體外診斷市場的市場限制與挑戰
- 定價和贖回方面的壓力
- 監理合規（體外診斷醫療器材法規）的複雜性
- 人力資源、資金和互通性方面的限制
體外診斷市場：市場機會
- 分子診斷和基因組學的擴展
- 新興市場和即時護理領域的擴張

第4章影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章監理分析

美國
歐洲
日本
中國

第6章體外診斷市場的波特五力分析

供應商的議價能力
買方的議價能力
新進入者的威脅
替代品的威脅
競爭公司之間的競爭

第7章體外診斷市場評估

依產品類型
- 裝置
- 試劑
- 其他
依測試方法
- 免疫診斷
- 血液學
- 分子診斷
- 臨床化學
依測試類型
- 實驗室檢測
- 即時偵測（POC）
檢體型
- 血
- 尿
- 唾液
依用途
- 腫瘤學
- 免疫學
- 感染疾病
- 循環系統
- 腎臟病學
依最終用戶
- 醫院
- 診斷檢查室
依地區
- 北美洲
- 歐洲
- 亞太地區
- 世界其他地區

第8章體外診斷市場的競爭格局

市場集中度與結構
競爭定位與市場佔有率分析（加值服務）

第9章體外診斷市場新創企業資金籌措與投資趨勢

第10章體外診斷市場：公司概況與產品概況

F. Hoffmann-La Roche Ltd
- 公司概況
- 公司簡介
- 財務概覽
- 服務組合
- 戰略方法/熵
Abbott
- 產品系列
FUJIFILM Corporation
Sysmex Corporation
Siemens Healthcare GmbH
BD
Seegene Inc.
Beckman Coulter, Inc.（Danaher Corporation）
QIAGEN
bioMerieux SA

第11章 KOL的觀點

第12章專案方法

第13章關於 DelveInsight

第14章免責聲明與聯絡方式

簡介目錄圖表

Product Code: DIMDCL0470

In Vitro Diagnostics Market Summary

Overview:

The In Vitro Diagnostics (IVD) market is estimated at USD 112.80 billion in 2025 and is projected to reach USD 189.40 billion by 2034. Growth is anchored in the rising global burden of chronic and infectious diseases, rapid advances in molecular diagnostics and laboratory automation, and expanding adoption of point-of-care and personalized testing.
The global In Vitro Diagnostics market is growing at a CAGR of 6.0% during the forecast period from 2026 to 2034.
By product type, the reagents segment dominated the In Vitro Diagnostics market with a 65% share in 2025.
By technique, the immunodiagnostics segment dominated the In Vitro Diagnostics market with a 29% share in 2025.
By test type, the laboratory-based tests segment dominated the In Vitro Diagnostics market with an 82% share in 2025.
By sample type, the blood segment dominated the In Vitro Diagnostics market with a 54% share in 2025.
By application, the infectious diseases segment dominated the In Vitro Diagnostics market with a 40% share in 2025.
By end user, the hospitals segment dominated the In Vitro Diagnostics market with a 44% share in 2025.
North America dominated the global In Vitro Diagnostics market revenue with a 39% share in 2025, representing the highest regional market share globally.

In vitro diagnostics (IVD) are tests, reagents, instruments, and systems used to examine specimens such as blood, urine, and saliva outside the body to detect, diagnose, monitor, and manage diseases and health conditions. IVD products range from simple lateral-flow strips to fully automated, high-throughput laboratory analyzers and complex molecular and next-generation sequencing platforms, and they underpin the majority of clinical decisions made across hospitals, diagnostic laboratories, physician offices, and home settings. The market is organized by product type across instruments, reagents, and other consumables; by technique, including immunodiagnostics, hematology, molecular diagnostics, and clinical chemistry; by test type, spanning laboratory-based and point-of-care (POC) tests; by sample type, led by blood, urine, and saliva; by application, encompassing oncology, immunology, infectious diseases, cardiology, and nephrology; and by end user, led by hospitals and diagnostic laboratories. Driven by the rising global burden of chronic and infectious disease, an aging population, the shift toward personalized and companion diagnostics, and continuous innovation in molecular testing, automation, and digital laboratory workflows, in vitro diagnostics have become indispensable infrastructure underpinning modern, evidence-based healthcare delivery.

In Vitro Diagnostics Market Key Growth Drivers

The rising global burden of chronic and infectious diseases is expanding diagnostic testing volumes, with cardiovascular disease, diabetes, cancer, and respiratory infections driving sustained demand for laboratory and point-of-care testing.
Rapid technological advancement, including next-generation sequencing, automated immunoassay platforms, and AI-integrated laboratory workflows, is improving diagnostic speed, accuracy, and throughput, exemplified by Roche's February 2025 launch of its SBX sequencing platform.
Growing adoption of point-of-care testing is decentralizing diagnostics away from central laboratories, enabling faster clinical decision-making in hospitals, physician offices, and community settings.
The expansion of personalized medicine and companion diagnostics is increasing demand for biomarker-based oncology testing that matches patients to targeted therapies.
An aging global population is expanding demand for chronic disease monitoring and preventive screening, with the population aged 60 and above projected to nearly double between 2015 and 2050.
Continued regulatory clearances and expanding test menus, including BD's November 2025 FDA clearance and CE-IVDR certification for its enteric bacterial panels on the BD COR system, are broadening the addressable testing landscape.
Rising mergers, acquisitions, and investment activity, including QIAGEN's planned acquisition of Parse Biosciences and Abbott's 2026 acquisition of Exact Sciences, are reshaping the competitive landscape and expanding technology portfolios.

Key Companies in In Vitro Diagnostics Market

The competitive landscape is led by the following active device manufacturers:

F. Hoffmann-La Roche Ltd
Abbott
FUJIFILM Corporation
Sysmex Corporation
Siemens Healthcare GmbH
BD
Seegene Inc
Beckman Coulter, Inc (Danaher Corporation)
QIAGEN
bioMerieux SA

Factors Contributing to the Growth of the In Vitro Diagnostics Market

Market Drivers

Rising Global Burden of Chronic and Infectious Diseases

The most powerful driver of the In Vitro Diagnostics market is the escalating global burden of chronic and infectious diseases. Cardiovascular disease, diabetes, cancer, and respiratory conditions continue to rise in prevalence, while infectious diseases such as HIV, tuberculosis, hepatitis, and seasonal respiratory pathogens remain significant public health challenges. Each of these conditions depends on laboratory and point-of-care testing for diagnosis, staging, and ongoing monitoring, generating high, recurring testing volumes across hospitals, diagnostic laboratories, and community settings. As disease prevalence climbs and screening programs expand, demand for immunodiagnostic, molecular, hematology, and clinical chemistry testing grows in step, anchoring durable, multi-year demand for IVD instruments, reagents, and services through 2034.

Technological Advancements in Molecular Diagnostics and Automation

Continuous innovation in molecular diagnostics, next-generation sequencing, and laboratory automation is expanding the clinical utility and adoption of IVD testing. Automated, high-throughput analyzers reduce turnaround time and manual error, while multiplex molecular panels allow simultaneous detection of multiple pathogens or biomarkers from a single sample. Roche's February 2025 launch of its SBX (Sequencing by Expansion) platform illustrates the pace of platform innovation reshaping the molecular diagnostics landscape. AI-integrated laboratory information systems and digital pathology tools are further improving diagnostic accuracy and workflow efficiency. As laboratories modernize infrastructure to handle rising test volumes with constrained staffing, adoption of next-generation automated and molecular platforms continues to accelerate, reinforcing sustained market growth.

Market Restraints

Despite strong underlying demand, the In Vitro Diagnostics market faces material constraints. Pricing and reimbursement pressure across major healthcare systems is compressing margins, particularly for high-volume reagent and consumable categories, while payers increasingly scrutinize the cost-effectiveness of newer molecular and companion diagnostic tests. Stringent and evolving regulatory frameworks, including the European Union's In Vitro Diagnostic Regulation (IVDR), have materially lengthened approval timelines and raised compliance costs, disproportionately burdening smaller manufacturers and niche test developers. High upfront capital requirements for automated analyzers and molecular platforms constrain adoption among smaller laboratories and in emerging markets, while consolidation among reference laboratory networks concentrates purchasing power and intensifies pricing competition among suppliers. A shortage of skilled laboratory professionals and molecular diagnostics specialists constrains testing capacity growth in several regions, and data privacy, interoperability, and cybersecurity concerns surrounding connected diagnostic platforms and laboratory information systems add further complexity. Uneven reimbursement and adoption of advanced testing across geographies, together with ongoing pricing pressure in high-volume categories such as reagent rental agreements, temper the pace of growth, even as the underlying drivers of disease burden, technological innovation, and personalized medicine remain firmly intact.

In Vitro Diagnostics Market Segment Analysis

The In Vitro Diagnostics Market Product Type (Instruments, Reagents, and Others), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Clinical Chemistry, and Others), Test Type (Laboratory-Based Tests and Point-of-Care (POC) Tests), Sample Type (Blood, Urine, Saliva, and Others), Application (Oncology, Immunology, Infectious Diseases, Cardiology, Nephrology, and Others), End User (Hospitals, Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Reagents. The Reagents category is expected to dominate the market.

Dominant: Reagents ~ 65%

The reagents segment accounted for 65% of the In Vitro Diagnostics market in 2025. Reagents are the leading product type because they are consumed with every single test performed, generating high-frequency, recurring revenue that scales directly with rising testing volumes across hospitals, diagnostic laboratories, and point-of-care settings. Unlike instruments, which represent a durable, largely one-time capital purchase, reagents and consumable kits must be continuously replenished, and many manufacturers use placement models that tie reagent purchase commitments to installed analyzer bases, reinforcing recurring demand. The breadth of immunoassay, molecular, hematology, and clinical chemistry reagent portfolios, combined with expanding test menus, sustains the segment's scale. While instruments are the fastest-growing product category as laboratories invest in automation and next-generation platforms, the sheer volume and recurring nature of reagent consumption secures the segment's leadership across the forecast period.

By Technique

Dominant Subsegment: Immunodiagnostics. The immunodiagnostics category is expected to dominate the market.

Dominant: Immunodiagnostics ~ 29%

The immunodiagnostics segment accounted for 29% of the In Vitro Diagnostics market in 2025. Immunodiagnostics is the leading technique because immunoassay platforms underpin the diagnosis and monitoring of a vast range of conditions, including infectious diseases, cardiac biomarkers, hormonal disorders, and oncology markers, and are widely deployed across hospitals and reference laboratories on fully automated, high-throughput analyzers. The breadth of approved immunoassay panels, combined with rising demand for biomarker-based testing in cardiology and oncology, sustains great and dependable demand for immunodiagnostic instruments and reagents. Beckman Coulter's expanding portfolio of neurodegenerative disease immunoassays, developed in partnership with Fujirebio, illustrates continued innovation in the segment. While molecular diagnostics is growing rapidly on the back of infectious disease and oncology testing, the established clinical role and breadth of immunodiagnostic applications secure the segment's leadership across the forecast period.

In Vitro Diagnostics Market Region Analysis

Dominant Region: North America

Dominant: North America ~ 39% (Largest)

North America accounted for 39% of the global In Vitro Diagnostics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a highly developed healthcare infrastructure, extensive laboratory networks, strong reimbursement frameworks, and clear FDA regulatory pathways, particularly in the United States. North America hosts the largest concentration of hospital and reference laboratory testing capacity and benefits from the presence of leading manufacturers, including Abbott, BD, and Beckman Coulter, alongside a dense distribution network. Rising chronic disease prevalence, high testing volumes, and continued investment in automated and molecular diagnostic platforms drive substantial demand across the region. Heavy investment in next-generation hematology, immunoassay, and molecular platforms, combined with active M&A and capacity expansion by major manufacturers, anchors the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the In Vitro Diagnostics market. The region's elevated CAGR is driven by rising chronic and infectious disease prevalence, rapid expansion of hospital and laboratory infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China is expanding domestic molecular and immunodiagnostic manufacturing capacity, Japan continues to lead in automated hematology and immunoassay innovation through companies such as Sysmex and FUJIFILM, India is scaling low-cost diagnostic manufacturing and point-of-care adoption, and South Korea's Seegene continues to expand its multiplex molecular diagnostics footprint globally. Government healthcare investment, expanding insurance coverage, and rising disease screening programs are accelerating adoption across the region, positioning Asia-Pacific as the principal source of incremental IVD market growth over the forecast period.

Regional Commentary

North America

North America accounted for 39% of the global In Vitro Diagnostics market revenue in 2025. The United States dominates on the strength of its healthcare infrastructure, laboratory network density, FDA regulatory clarity, and strong reimbursement environment, while continued investment in automated hematology, immunoassay, and molecular platforms by leading manufacturers reinforces its leadership.

Europe

Europe is a large and advanced regional market, supported by established EMA and IVDR regulatory frameworks, strong public healthcare systems, and a deep base of diagnostic manufacturers including Roche, Siemens Healthcare, and bioMerieux. bioMerieux's planned investment exceeding EUR 250 million in a new French manufacturing facility for its BIOFIRE molecular testing range reinforces the region's role in supplying both diagnostic reagents and instruments across Germany, France, the United Kingdom, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising disease prevalence, rapid healthcare infrastructure build-out, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Sysmex's continued rollout of next-generation hematology platforms and Seegene's expanding multiplex molecular diagnostics portfolio are accelerating regional adoption and manufacturing capacity.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare infrastructure, rising demand for infectious disease and chronic disease testing, and efforts to align regulatory frameworks with global standards are gradually broadening access, while international partnerships and government agreements, such as Nigeria's 2024 diagnostic infrastructure agreement with Abbott and Siemens Healthineers, support the build-out of regional testing capacity.

In Vitro Diagnostics Market Competitive Landscape

The In Vitro Diagnostics market is classified as Moderately Concentrated. A group of large, diversified players with broad product portfolios and global manufacturing reach, including F. Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, and Beckman Coulter (Danaher Corporation), secures large hospital and laboratory contracts and anchors the top tier, while specialized and fast-scaling providers such as Seegene, QIAGEN, bioMerieux, Sysmex, and FUJIFILM Corporation compete through technology differentiation, regional manufacturing strength, and targeted disease-area expertise, increasing competition in the fastest-growing molecular and point-of-care segments.

The competitive landscape can be evaluated across the following dimensions:

Market concentration: Moderately concentrated, with diversified global players leading and a fast-growing field of specialized molecular and point-of-care diagnostics providers.
Leading players: F. Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, and Beckman Coulter (Danaher Corporation) anchor the top tier through broad product portfolios and global distribution networks; industry estimates place Roche's global IVD market share at approximately 20%.
Geographic reach: Leaders operate global, regionally distributed manufacturing and distribution networks essential for supplying hospitals and laboratories across developed and emerging markets.
Service portfolio strength: Top players offer end-to-end instrument, reagent, software, and service portfolios spanning immunodiagnostics, molecular diagnostics, hematology, and clinical chemistry.
Technology leadership: Ownership of proprietary platforms, including Roche's SBX sequencing technology and Seegene's multiplex PCR chemistries, is a decisive competitive advantage.
Strategic partnerships: Tie-ups between manufacturers and technology specialists, such as Beckman Coulter's expanded partnership with Fujirebio for blood-based neurodegenerative disease diagnostics, extend technological reach.
M&A activity: Active consolidation, including QIAGEN's planned acquisition of Parse Biosciences, Abbott's acquisition of Exact Sciences, and Siemens Healthineers' exploration of a diagnostics division divestiture.
Manufacturing capabilities: Automated, high-throughput instrument platforms and scalable reagent manufacturing capacity are key competitive moats.
Innovation focus: Molecular diagnostics scale-up, point-of-care decentralization, AI-integrated laboratory workflows, and blood-based biomarker testing for oncology and neurodegenerative disease.

In Vitro Diagnostics Market Recent Developmental Activities

In February 2025, F. Hoffmann-La Roche Ltd. launched its SBX (Sequencing by Expansion) platform, expanding its molecular diagnostics and sequencing technology portfolio. Strategic significance: Strengthens Roche's next-generation sequencing capabilities and reinforces its position as the leading integrated diagnostics provider.

In 2026, Abbott completed its acquisition of Exact Sciences, significantly expanding its oncology screening and diagnostics portfolio. Strategic significance: Broadens Abbott's presence in cancer diagnostics and companion testing, a key growth application.

In Vitro Diagnostics Market Segmentation

In Vitro Diagnostics Market by Product Type

Instruments
Reagents
Others

In Vitro Diagnostics Market by Technique

Immunodiagnostics
Hematology
Molecular Diagnostics
Clinical Chemistry
Others

In Vitro Diagnostics Market by Test Type

Laboratory-Based Tests
Point-of-Care (POC) Tests

In Vitro Diagnostics Market by Sample Type

Blood
Urine
Saliva
Others

In Vitro Diagnostics Market by Application

Oncology
Immunology
Infectious Diseases
Cardiology
Nephrology
Others

In Vitro Diagnostics Market by End User

Hospitals
Diagnostic Laboratories
Others

In Vitro Diagnostics Market by Geography

North America In Vitro Diagnostics Market
United States In Vitro Diagnostics Market Size in USD million (2023-2034)
Canada In Vitro Diagnostics Market Size in USD million (2023-2034)
Mexico In Vitro Diagnostics Market Size in USD million (2023-2034)
Europe In Vitro Diagnostics Market
Germany In Vitro Diagnostics Market Size in USD million (2023-2034)
United Kingdom In Vitro Diagnostics Market Size in USD million (2023-2034)
France In Vitro Diagnostics Market Size in USD million (2023-2034)
Italy In Vitro Diagnostics Market Size in USD million (2023-2034)
Spain In Vitro Diagnostics Market Size in USD million (2023-2034)
Rest of Europe In Vitro Diagnostics Market Size in USD million (2023-2034)
Asia-Pacific In Vitro Diagnostics Market
China In Vitro Diagnostics Market Size in USD million (2023-2034)
Japan In Vitro Diagnostics Market Size in USD million (2023-2034)
India In Vitro Diagnostics Market Size in USD million (2023-2034)
Australia In Vitro Diagnostics Market Size in USD million (2023-2034)
South Korea In Vitro Diagnostics Market Size in USD million (2023-2034)
Rest of Asia-Pacific In Vitro Diagnostics Market Size in USD million (2023-2034)
Rest of the World (RoW) In Vitro Diagnostics Market
Middle East In Vitro Diagnostics Market Size in USD million (2023-2034)
Africa In Vitro Diagnostics Market Size in USD million (2023-2034)
South America In Vitro Diagnostics Market Size in USD million (2023-2034)

Key Takeaways from the In Vitro Diagnostics Market Report Study

Market size analysis for the current in vitro diagnostics market size (2025), and market forecast for 9 years (2026 to 2034).
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
Key companies dominating the global in vitro diagnostics market.
Various opportunities available for competitors in the in vitro diagnostics market space.
What are the top-performing segments in 2025? How will these segments perform in 2034?
Which are the top-performing regions and countries in the current in vitro diagnostics market scenario?
Which are the regions and countries where companies should concentrate their opportunities for in vitro diagnostics market growth in the future?

Target audience who can benefit from this in vitro diagnostics market report study

In vitro diagnostics product providers
Research organizations and consulting companies
In vitro diagnostics-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in in vitro diagnostics
Various end-users who want to know more about the in vitro diagnostics market and the latest technological developments in the in vitro diagnostics market.

Frequently Asked Questions:

Q1. What is the growth rate of the in vitro diagnostics market?

The in vitro diagnostics market is projected to expand at a CAGR of 6.0% during the forecast period from 2026-2034.

Q2. What is the market size of the in vitro diagnostics market?

The In Vitro Diagnostics market is estimated at USD 112.80 billion in 2025 and is projected to reach USD 189.40 billion by 2034.

Q3. Which region dominates the in vitro diagnostics market?

North America dominated the In Vitro Diagnostics market with a 39% share of global revenue in 2025, supported by a highly developed healthcare infrastructure, extensive laboratory networks, strong reimbursement frameworks, FDA regulatory clarity, and the presence of leading manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the in vitro diagnostics market?

The principal drivers are the rising global burden of chronic and infectious diseases; rapid technological advancement in molecular diagnostics, automation, and AI-integrated laboratory workflows; growing adoption of point-of-care testing; expansion of personalized medicine and companion diagnostics; an aging global population; and rising mergers, acquisitions, and investment activity across the diagnostics industry.

Q5. Who are the major players in the in vitro diagnostics market?

The major players include F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc (Danaher Corporation), QIAGEN, and bioMerieux SA, among other active providers profiled in the Competitive Landscape section. F. Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, and Beckman Coulter lead through broad, diversified product portfolios and global distribution networks.

1. In Vitro Diagnostics Market Report Introduction

1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. In Vitro Diagnostics Market Executive Summary

2.1 Market at a Glance

3. In Vitro Diagnostics Market Key Factors Analysis

3.1 In Vitro Diagnostics Market Drivers
- 3.1.1 Rising Burden of Chronic and Infectious Diseases
- 3.1.2 Technological Advancements in Molecular Diagnostics
- 3.1.3 Growing Adoption of Point-of-Care Testing
- 3.1.4 Expansion of Personalized Medicine and Companion Diagnostics
3.2 In Vitro Diagnostics Market Restraints and Challenges
- 3.2.1 Pricing and Reimbursement Pressure
- 3.2.2 Regulatory Compliance Complexity (IVDR)
- 3.2.3 Workforce, Capital, and Interoperability Constraints
3.3 In Vitro Diagnostics Market Opportunities
- 3.3.1 Molecular Diagnostics and Genomics Scale-Up
- 3.3.2 Emerging-Market and Point-of-Care Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. In Vitro Diagnostics Market Porter's Five Forces Analysis

6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. In Vitro Diagnostics Market Assessment

7.1 By Product Type
- 7.1.1 Instruments
- 7.1.2 Reagents
- 7.1.3 Others
7.2 By Technique
- 7.2.1 Immunodiagnostics
- 7.2.2 Hematology
- 7.2.3 Molecular Diagnostics
- 7.2.4 Clinical Chemistry
- 7.2.5 Others
7.3 By Test Type
- 7.3.1 Laboratory-Based Tests
- 7.3.2 Point-of-Care (POC) Tests
7.4 By Sample Type
- 7.4.1 Blood
- 7.4.2 Urine
- 7.4.3 Saliva
- 7.4.4 Others
7.5 By Application
- 7.5.1 Oncology
- 7.5.2 Immunology
- 7.5.3 Infectious Diseases
- 7.5.4 Cardiology
- 7.5.5 Nephrology
- 7.5.6 Others
7.6 By End User
- 7.6.1 Hospitals
- 7.6.2 Diagnostic Laboratories
- 7.6.3 Others
7.7 By Geography
- 7.7.1 North America
  - 7.7.1.1 United States In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.1.2 Canada In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.1.3 Mexico In Vitro Diagnostics Market Size in USD million (2023-2034)
- 7.7.2 Europe
  - 7.7.2.1 Germany In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.2.2 United Kingdom In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.2.3 France In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.2.4 Italy In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.2.5 Spain In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.2.6 Rest of Europe In Vitro Diagnostics Market Size in USD million (2023-2034)
- 7.7.3 Asia-Pacific
  - 7.7.3.1 China In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.3.2 Japan In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.3.3 India In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.3.4 Australia In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.3.5 South Korea In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.3.6 Rest of Asia-Pacific In Vitro Diagnostics Market Size in USD million (2023-2034)
- 7.7.4 Rest of World
  - 7.7.4.1 Middle East In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.4.2 Africa In Vitro Diagnostics Market Size in USD million (2023-2034)
  - 7.7.4.3 South America In Vitro Diagnostics Market Size in USD million (2023-2034)

8. In Vitro Diagnostics Market Competitive Landscape

8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. In Vitro Diagnostics Market Startup Funding and Investment Trends

10. In Vitro Diagnostics Market Company and Product Profiles

10.1 F. Hoffmann-La Roche Ltd
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
10.2 Abbott
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
10.3 FUJIFILM Corporation
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
10.4 Sysmex Corporation
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
10.5 Siemens Healthcare GmbH
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
10.6 BD
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
10.7 Seegene Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
10.8 Beckman Coulter, Inc. (Danaher Corporation)
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
10.9 QIAGEN
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
10.10 bioMerieux SA
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.